Despite - or perhaps because of - multiple recent industry failures in the search for an effective drug against Alzheimer's disease (AD), Eisai Co. Ltd. is pushing ahead with a new research initiative in the US that will explore an immune approach to treating this and other forms of dementia.
Eisai Refocuses AiM As It Builds US Immuno-Dementia Research
Amid multiple industry drug failures in the sector, Eisai is opening a new US research facility to discover innovative therapies for dementia based on a long-standing immunology hypothesis.
More from Neurological
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.